Abstract Details

Title Validation of MRI radiological reports in pediatric MS according to the McDonald 2017 criteria: A Danish nationwide multicenter cohort study

Topic Multiple Sclerosis

Presentation(s) P13 - Poster Session 13 (8:00 AM-9:00 AM)

Poster/Presentation
Number 12-007

Background MRI allows demonstration of dissemination in space and time at the first demyelinating event. However, no pediatric MS studies have investigated the validity of MS-specific outcomes described in MRI radiological reports that clinicians rely on to make the MS diagnosis and to assess MS treatment.

Objective To validate MS-specific outcomes in hospital MRI reports in pediatric MS by comparing MS-specific outcomes in MRI reports with secondary MRI review of the MS-specific outcomes.

Design/Methods

A senior consultant and a resident neurologist extracted data on MS-specific outcomes from MRI reports at baseline and follow-up in children with MS onset during 2008–15 in Denmark. Gold standard was two expert neuroradiologists’ secondary MRI reviews. We estimated percent agreement and Kappa values by comparing data extracted from hospital MRI reports (what we want to test) with results from the secondary MRI reviews (our gold standard).

Results

Among 55 children with MS, we included 44 baseline and 48 follow-up MRIs. The median age at MS onset was 16.3 years (range 9.2?17.9).

Agreement between the MRI reports and the secondary MRI review ranged 68%–100% for MS-specific outcomes; agreement was higher when MRI outcomes were present. Kappa values ranged from 0.42 (“moderate”) to 1.00 (“excellent”). Kappa for fulfillment of the McDonald 2017 criteria was 0.60 on baseline MRI, and 0.53 on follow-up MRI. Kappa for a new lesion on follow-up MRI was 0.41.

Conclusions

Agreement was moderate to good for most MS-specific outcomes between MS neurologists’ data extraction from hospital MRI radiological reports compared with neuroradiologists’ secondary MRI reviews. The agreement was moderate for both fulfilling the McDonald 2017 criteria and acquiring a new lesion on follow-up MRI. We recommend structured MRI reporting in children suspected of acquired demyelinating syndromes to increase validity of hospital MRI reports and clinical use.

Authors/Disclosures
Magnus Spangsberg Boesen, MD (Herlev Hospital) PRESENTER	Dr. Spangsberg Boesen has nothing to disclose.
	No disclosure on file
Jurgita Ilginiene	No disclosure on file
Melinda Magyari, MD	Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Magyari has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Magyari has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Magyari has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. The institution of Dr. Magyari has received research support from The Danish MS Society. The institution of Dr. Magyari has received research support from Biogen. The institution of Dr. Magyari has received research support from Novartis. The institution of Dr. Magyari has received research support from Roche. The institution of Dr. Magyari has received research support from Merck. The institution of Dr. Magyari has received research support from Sanofi.
Morten B. Blinkenberg, MD, PhD (Danish MS Centre, Dept. of Neurology)	The institution of Morten Bjorn Blinkenberg, MD, PhD has received research support from Danish MS Society.